<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01614899</url>
  </required_header>
  <id_info>
    <org_study_id>D1001056</org_study_id>
    <secondary_id>JapicCTI-121859</secondary_id>
    <nct_id>NCT01614899</nct_id>
  </id_info>
  <brief_title>A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia</brief_title>
  <official_title>Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia &lt;Phase 3&gt;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients
      with schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2, 2012</start_date>
  <completion_date type="Actual">November 17, 2014</completion_date>
  <primary_completion_date type="Actual">November 17, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</measure>
    <time_frame>Baseline and 6 week</time_frame>
    <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease.
The change from baseline in CGI-S score (repeated measures) at each visit during the treatment phase is presented for the mITT population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Positive Subscale Scores at Week 6</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS Negative Subscale Scores at Week 6</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6</measure>
    <time_frame>Baseline and 6 weeks</time_frame>
    <description>The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From Baseline to 6 weeks</time_frame>
    <description>Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With TEAEs Leading to Discontinuation</measure>
    <time_frame>From Baseline to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)</measure>
    <time_frame>From Baseline to 6 weeks</time_frame>
    <description>Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">457</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SM-13496 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SM-13496 80mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM-13496 40mg</intervention_name>
    <description>once daily orally</description>
    <arm_group_label>SM-13496 40mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM-13496 80mg</intervention_name>
    <description>once daily orally</description>
    <arm_group_label>SM-13496 80mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient meets DSM-IV-TR criteria for schizophrenia.

          -  Patient is aged 18 through 74 years at informed consent.

          -  Patient understands the objectives, procedures, and possible benefits and risks of the
             study and who provide written voluntarily consent to participate in the study

        Exclusion Criteria:

          -  Patient has a history of neuroleptic malignant syndrome, water intoxication, or
             paralytic ileus.

          -  Patient has Parkinson's disease.

          -  Patient has a history or complication of malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Drug development Division</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippon Pharma Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>69 Sites</name>
      <address>
        <city>Tokyo, Etc</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>22 Sites</name>
      <address>
        <city>Seoul, Etc</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10 Sites</name>
      <address>
        <city>Kuala Lumpur, Etc</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>14 Sites</name>
      <address>
        <city>Taipei, Etc</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 6, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <results_first_submitted>July 20, 2017</results_first_submitted>
  <results_first_submitted_qc>December 22, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 19, 2018</results_first_posted>
  <last_update_submitted>December 22, 2017</last_update_submitted>
  <last_update_submitted_qc>December 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lurasidone Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SM-13496 (Lurasidone HCl) 40mg</title>
          <description>SM-13496 40 mg was administered orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>SM-13496 (Lurasidone HCl) 80mg</title>
          <description>SM-13496 80 mg was administered orally once daily.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo was administered orally once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="150"/>
                <participants group_id="P2" count="155"/>
                <participants group_id="P3" count="152"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="42"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SM-13496 (Lurasidone HCl) 40mg</title>
          <description>SM-13496 40 mg was administered orally once daily.</description>
        </group>
        <group group_id="B2">
          <title>SM-13496 (Lurasidone HCl) 80mg</title>
          <description>SM-13496 80 mg was administered orally once daily.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo was administered orally once daily.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="152"/>
            <count group_id="B3" value="142"/>
            <count group_id="B4" value="439"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.0" spread="13.1"/>
                    <measurement group_id="B2" value="43.6" spread="13.9"/>
                    <measurement group_id="B3" value="42.9" spread="13.5"/>
                    <measurement group_id="B4" value="42.9" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</title>
        <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
        <time_frame>Baseline and 6 week</time_frame>
        <population>mITT (modified intent-to-treat) population</population>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 (Lurasidone HCl) 40mg</title>
            <description>SM-13496 40 mg was administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 (Lurasidone HCl) 80mg</title>
            <description>SM-13496 80 mg was administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Week 6</title>
          <description>The PANSS is an interview-based measure of the severity of psychopathology in adults with psychotic disorders. The measure is comprised of 30 items and three subscales: the Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility; the Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms; and the General Psychopathology subscale addresses other symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS total score is the sum of all 30 items and ranges from 30 through 210. A higher score is associated with greater illness severity.</description>
          <population>mITT (modified intent-to-treat) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.9" spread="1.72"/>
                    <measurement group_id="O2" value="-17.3" spread="1.67"/>
                    <measurement group_id="O3" value="-13.1" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.050</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-4.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.52</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.080</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-4.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.91</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6</title>
        <description>CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease.
The change from baseline in CGI-S score (repeated measures) at each visit during the treatment phase is presented for the mITT population</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>mITT (modified intent-to-treat) population</population>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 (Lurasidone HCl) 40mg</title>
            <description>SM-13496 40 mg was administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 (Lurasidone HCl) 80mg</title>
            <description>SM-13496 80 mg was administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score at Week 6</title>
          <description>CGI-S is a clinician-rated assessment of the participant's current disease state on a 7-point scale, where a higher score is associated with greater severity of the disease.
The change from baseline in CGI-S score (repeated measures) at each visit during the treatment phase is presented for the mITT population</description>
          <population>mITT (modified intent-to-treat) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.100"/>
                    <measurement group_id="O2" value="-0.97" spread="0.097"/>
                    <measurement group_id="O3" value="-0.79" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.594</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.354</ci_lower_limit>
            <ci_upper_limit>0.203</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.199</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.453</ci_lower_limit>
            <ci_upper_limit>0.095</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Positive Subscale Scores at Week 6</title>
        <description>The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>mITT (modified intent-to-treat) population</population>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 (Lurasidone HCl) 40mg</title>
            <description>SM-13496 40 mg was administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 (Lurasidone HCl) 80mg</title>
            <description>SM-13496 80 mg was administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Positive Subscale Scores at Week 6</title>
          <description>The PANSS is comprised of 30 items and three subscales. The Positive subscale contains seven questions to assess delusions, conceptual disorganization, hallucinations behavior, excitement, grandiosity, suspiciousness/persecution, and hostility. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Positive subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.</description>
          <population>mITT (modified intent-to-treat) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.4" spread="0.54"/>
                    <measurement group_id="O2" value="-6.2" spread="0.52"/>
                    <measurement group_id="O3" value="-4.2" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.143</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.60</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.40</ci_lower_limit>
            <ci_upper_limit>-0.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS Negative Subscale Scores at Week 6</title>
        <description>The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>mITT (modified intent-to-treat) population</population>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 (Lurasidone HCl) 40mg</title>
            <description>SM-13496 40 mg was administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 (Lurasidone HCl) 80mg</title>
            <description>SM-13496 80 mg was administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS Negative Subscale Scores at Week 6</title>
          <description>The PANSS is comprised of 30 items and three subscales. The Negative subscale contains seven questions to assess blunted effect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, lack of motivation, and similar symptoms. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS Negative subscale score is the sum of all 7 items and ranges from 7 through 49. A higher score is associated with greater illness severity.</description>
          <population>mITT (modified intent-to-treat) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="0.46"/>
                    <measurement group_id="O2" value="-3.4" spread="0.45"/>
                    <measurement group_id="O3" value="-2.9" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.116</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.27</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.388</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.80</ci_lower_limit>
            <ci_upper_limit>0.70</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6</title>
        <description>The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.</description>
        <time_frame>Baseline and 6 weeks</time_frame>
        <population>mITT (modified intent-to-treat) population</population>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 (Lurasidone HCl) 40mg</title>
            <description>SM-13496 40 mg was administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 (Lurasidone HCl) 80mg</title>
            <description>SM-13496 80 mg was administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PANSS General Psychopathology Subscale Scores at Week 6</title>
          <description>The PANSS is comprised of 30 items and three subscales. The General Psychopathology subscale addresses other 16 symptoms such as anxiety, somatic concern, and disorientation. An anchored Likert scale from 1-7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. The PANSS General Psychopathology subscale score is the sum of all 16 items and ranges from 16 through 112. A higher score is associated with greater illness severity.</description>
          <population>mITT (modified intent-to-treat) population</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="0.85"/>
                    <measurement group_id="O2" value="-7.9" spread="0.83"/>
                    <measurement group_id="O3" value="-6.3" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.87</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.174</p_value>
            <method>Mixed Model for Repeated Measures</method>
            <param_type>LS Mean difference</param_type>
            <param_value>-1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.93</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.</description>
        <time_frame>From Baseline to 6 weeks</time_frame>
        <population>Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 (Lurasidone HCl) 40mg</title>
            <description>SM-13496 40 mg was administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 (Lurasidone HCl) 80mg</title>
            <description>SM-13496 80 mg was administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>Proportion of participants with treatment-emergent adverse events. An adverse event was defined as any untoward medical occurrence in a patient treated with a medicinal (investigational) product and which did not necessarily have a causal relationship with this treatment. Treatment-emergent adverse events (TEAEs) were defined as adverse events with a start date on or after the date of the first dose through the end of follow-up, or adverse events occurring before the date of first dose and worsening during the treatment or follow-up period.</description>
          <population>Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With TEAEs Leading to Discontinuation</title>
        <time_frame>From Baseline to 6 weeks</time_frame>
        <population>Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 (Lurasidone HCl) 40mg</title>
            <description>SM-13496 40 mg was administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 (Lurasidone HCl) 80mg</title>
            <description>SM-13496 80 mg was administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With TEAEs Leading to Discontinuation</title>
          <population>Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)</title>
        <description>Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.</description>
        <time_frame>From Baseline to 6 weeks</time_frame>
        <population>Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.</population>
        <group_list>
          <group group_id="O1">
            <title>SM-13496 (Lurasidone HCl) 40mg</title>
            <description>SM-13496 40 mg was administered orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>SM-13496 (Lurasidone HCl) 80mg</title>
            <description>SM-13496 80 mg was administered orally once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo was administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Treatment-emergent Serious Adverse Events (SAEs)</title>
          <description>Proportion of participants with treatment-emergent adverse events. A serious adverse event was defined as an AE that met one or more of the following criteria: Resulted in death; Was life-threatening (i.e., a patient was at immediate risk of death at the time of the event, not an event where occurrence in a more severe form might have caused death); Required hospitalization or prolongation of existing hospitalization; Resulted in persistent or significant disability or incapacity; Was a congenital anomaly or birth defect; Was an important medical event that might jeopardize the patient or might require medical intervention to prevent one of the outcomes listed above.</description>
          <population>Safety population defined as subjects who receive at least one dose of the study drug in the treatment phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="150"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline to 6 weeks</time_frame>
      <desc>TEAEs were defined as adverse events (AEs) with a start date on or after the date of the first dose through the end of follow-up, or AEs occurring before the date of first dose and worsening during the treatment or follow-up period. Both TEAEs and treatment-emergent serious AEs are presented for the safety population defined as subjects who receive at least one of the study drug in the treatment phase.
Patients experiencing multiple AEs are counted once in each category.</desc>
      <group_list>
        <group group_id="E1">
          <title>SM-13496 (Lurasidone HCl) 40mg</title>
          <description>SM-13496 40 mg was administered orally once daily.</description>
        </group>
        <group group_id="E2">
          <title>SM-13496 (Lurasidone HCl) 80mg</title>
          <description>SM-13496 80 mg was administered orally once daily.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo was administered orally once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="94" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyskinesia oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Lip dry</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Periproctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Application site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Adenoviral conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Gingival infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tooth avulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Subcutaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Monocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Skin test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Electrocardiogram PR shortened</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urobilinogen urine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diet refusal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle rigidity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Osteoarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tardive dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Impulse-control disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Persecutory delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Catatonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Self injurious behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Bladder spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Skin erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Scar pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Wisdom teeth removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="151"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="154"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="151"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regional Function Head of CNS Research</name_or_title>
      <organization>Clinical Research, Drug Development Division</organization>
      <phone>+81-3-5159-2519</phone>
      <email>cc@ds-pharma.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

